that future is here
IMAGINE A FUTURE WHERE CREATING THE NEXT LIFE-CHANGING IMMUNOTHERAPY WAS AS EASY AS CLICKING ‘SEARCH’.
INTRODUCING OUR PLATFORM
Welcome to EMLy™ Co-pilot
The world’s leading repertoire decoding technology using cutting-edge AI tools and billions of protein sequences from public and private sources to help you speed up your drug discovery.
Large Language Model (LLM)
Protein Large Language models form the heart of our technology, by pulling together large public domain sequence bases and our own unique datasets of TCRs and Antibody repertoires our systems contribute all across the preclinical landscape.
1. Error Correction of NGS Sequence
2. Discovery of Binding molecules
3. Affinity improvements
4. Cross Reactivity prediction
5. Developability of candidates
Movement and Generative AI
The huge successes of AlphaFold is the basis of modern drug discovery, however this advance solves the formation of a static structure and does not consider the natural dynamism of biochemical reactions. We extend these advances by incorporating molecular movement into our assessment of binding/affinity and expression.
Repertoire
The diversity of TCR and BCR sequences derived from patient samples is the data source which powers our technology. We embed them, create networks to understand their diversity. By deconvoluting their specificity we can open the door to utilising the repertoire for target and therapeutic drug discovery.
Join us in our journey as we explore how Etcembly with EMLy Co-pilot is transforming the landscape of drug discovery with AI-driven solutions.
Large Language Model (LLM)
Protein Large Language models form the heart of our technology, by pulling together large public domain sequence bases and our own unique datasets of TCRs and Antibody repertoires our systems contribute all across the preclinical landscape.
1. Error Correction of NGS Sequence
2. Discovery of Binding molecules
3. Affinity improvements
4. Cross Reactivity prediction
5. Developability of candidates
Movement and Generative AI
The huge successes of AlphaFold is the basis of modern drug discovery, however this advance solves the formation of a static structure and does not consider the natural dynamism of biochemical reactions. We extend these advances by incorporating molecular movement into our assessment of binding/affinity and expression.
Repertoire .
The diversity of TCR and BCR sequences derived from patient samples is the data source which powers our technology. We embed them, create networks to understand their diversity. By deconvoluting their specificity we can open the door to utilising the repertoire for target and therapeutic drug discovery.